New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.46 1.12 +1.92%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Bristol Myers Squibb Company (BMY) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Bristol Myers Squibb Company (BMY) trades at a EV/FCF of 16.1×. Over the past ten years it has ranged from 7.8× (October 2025) to 389× (June 2016); the current reading is higher than 62% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 11.2× 1.97%
FY2024 11.0× 1.89%
FY2023 10.8× (29.85%)
FY2022 15.4× 41.26%
FY2021 10.9× (17.12%)
FY2020 13.2× (31.11%)
FY2019 19.1× 39.86%
FY2018 13.7× (43.53%)
FY2017 24.2× (55.32%)
FY2016 54.1× (40.63%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 17.0× 29.83%
Jun 2026 13.1× (1.10%)
Mar 2026 13.2× 17.92%
Dec 2025 11.2× 38.15%
43 more quarters

Against its own ten years

Low 7.8× High 389×
Ten-year median 14.2×
Current reading's percentile 68

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on BMY